Angitia Biopharmaceuticals
PrivateLast Round
Series D
Feb 5, 2026
Total Funding Raised
$406M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Angitia Biopharmaceuticals is a biotechnology company that discovers and develops innovative biologic therapies for serious musculoskeletal diseases, including osteoporosis, osteogenesis imperfecta, and spinal fusion.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Angitia Biopharmaceuticals Comparables
Compare Angitia Biopharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| DiscGenics | 82% | |
| Transcenta Holding | 78% | |
| Mesentech Inc. | 78% |
Angitia Biopharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Feb 5, 2026 | ||||
| Series C | Dec 11, 2024 | ||||
| Series B Extension | Jan 1, 2024 | ||||
| Series B Extension | Oct 25, 2023 | ||||
| Series B | Oct 31, 2021 | ||||
Series A | Aug 18, 2020 |
Key People
Founding team and executive leadership
Angitia Biopharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| OrbiMed Asia | Series A |
| Bain Capital Life Sciences | Series D, Series C |
| Janus Henderson Group | Series D, Series C |
| RA Capital Management | Series D |
| Oriza Holdings | Series A, Series B, Series B Extension |
| Firstred Capital | Series B |
| Hillhouse Investment | Series D, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 24, 2026
Monthly visitors increased 119% MoM.
- May 29, 2026
Osteoporosis and OI programs are in global Phase 2 studies.
Angitia Biopharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Angitia Biopharmaceuticals's valuation, stock price, and market status.
Is Angitia a public or private company?
Angitia is a private company.
What is the current stock price of Angitia?
Angitia is a private company with no public stock price. No recent secondary market data is available.
How much is Angitia worth (valuation)?
Valuation information for Angitia is not publicly available.
Can I buy Angitia stock?
Angitia shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Angitia's last funding round?
Angitia's most recent funding round was Series D on February 5, 2026.
Who are the main investors in Angitia?
Key investors in Angitia include Bain Capital Life Sciences, Hillhouse Investment, Frazier Life Sciences, Venrock.
Will Angitia IPO soon?
No public IPO plans have been announced for Angitia.
How can I track Angitia secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Angitia's secondary market activity and sign up for updates.